Charles Schwab’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Buy |
980,321
+189,192
| +24% | +$3.58M | ﹤0.01% | 1894 |
|
|
2026
Q1 | $17.2M | Buy |
791,129
+25,746
| +3% | +$498K | ﹤0.01% | 1825 |
|
|
2025
Q4 | $16.5M | Buy |
765,383
+156,232
| +26% | +$3.29M | ﹤0.01% | 1872 |
|
|
2025
Q3 | $11.7M | Sell |
609,151
-64,726
| -10% | -$1.15M | ﹤0.01% | 2043 |
|
|
2025
Q2 | $11.5M | Buy |
673,877
+27,586
| +4% | +$1.18M | ﹤0.01% | 1943 |
|
|
2025
Q1 | $41.2M | Buy |
646,291
+22,542
| +4% | +$2.37M | 0.01% | 1199 |
|
|
2024
Q4 | $75.8M | Buy |
623,749
+12,000
| +2% | +$1.47M | 0.01% | 816 |
|
|
2024
Q3 | $76.4M | Buy |
611,749
+6,992
| +1% | +$967K | 0.01% | 821 |
|
|
2024
Q2 | $95.6M | Buy |
604,757
+15,318
| +3% | +$1.97M | 0.02% | 669 |
|
|
2024
Q1 | $76.3M | Buy |
589,439
+13,027
| +2% | +$1.6M | 0.02% | 751 |
|
|
2023
Q4 | $55.6M | Buy |
576,412
+16,061
| +3% | +$1.54M | 0.01% | 897 |
|
|
2023
Q3 | $67.9M | Buy |
560,351
+6,309
| +1% | +$713K | 0.02% | 700 |
|
|
2023
Q2 | $63.4M | Buy |
554,042
+34,078
| +7% | +$4.39M | 0.02% | 725 |
|
|
2023
Q1 | $71.7M | Buy |
519,964
+3,505
| +0.7% | +$455K | 0.02% | 625 |
|
|
2022
Q4 | $66.9M | Buy |
516,459
+21,819
| +4% | +$2.53M | 0.02% | 642 |
|
|
2022
Q3 | $54.7M | Buy |
494,640
+6,986
| +1% | +$704K | 0.02% | 703 |
|
|
2022
Q2 | $36.6M | Buy |
487,654
+8,369
| +2% | +$616K | 0.01% | 965 |
|
|
2022
Q1 | $37.4M | Buy |
479,285
+11,006
| +2% | +$843K | 0.01% | 1070 |
|
|
2021
Q4 | $42.2M | Buy |
468,279
+49,620
| +12% | +$4.24M | 0.01% | 1020 |
|
|
2021
Q3 | $38.7M | Buy |
418,659
+14,866
| +4% | +$1.15M | 0.01% | 1048 |
|
|
2021
Q2 | $31.4M | Buy |
403,793
+9,361
| +2% | +$710K | 0.01% | 1207 |
|
|
2021
Q1 | $29.4M | Buy |
394,432
+3,983
| +1% | +$368K | 0.01% | 1211 |
|
|
2020
Q4 | $66.6M | Buy |
390,449
+5,962
| +2% | +$883K | 0.03% | 614 |
|
|
2020
Q3 | $54M | Buy |
384,487
+24,308
| +7% | +$3.69M | 0.02% | 630 |
|
|
2020
Q2 | $57.8M | Buy |
360,179
+22,178
| +7% | +$3.02M | 0.03% | 562 |
|
|
2020
Q1 | $33.1M | Buy |
338,001
+7,210
| +2% | +$824K | 0.02% | 691 |
|
|
2019
Q4 | $42.7M | Buy |
330,791
+5,807
| +2% | +$586K | 0.02% | 711 |
|
|
2019
Q3 | $24.5M | Buy |
324,984
+18,575
| +6% | +$2.19M | 0.01% | 1005 |
|
|
2019
Q2 | $46.6M | Buy |
306,409
+24,932
| +9% | +$3.03M | 0.03% | 603 |
|
|
2019
Q1 | $33.5M | Buy |
281,477
+19,091
| +7% | +$2.45M | 0.02% | 783 |
|
|
2018
Q4 | $28.6M | Buy |
262,386
+24,140
| +10% | +$3.02M | 0.02% | 750 |
|
|
2018
Q3 | $38.5M | Buy |
238,246
+9,915
| +4% | +$1.36M | 0.03% | 669 |
|
|
2018
Q2 | $30.2M | Sell |
228,331
-92,125
| -29% | -$8.69M | 0.02% | 781 |
|
|
2018
Q1 | $23.7M | Buy |
320,456
+31,107
| +11% | +$2.07M | 0.02% | 894 |
|
|
2017
Q4 | $16.1M | Buy |
289,349
+20,796
| +8% | +$1.1M | 0.01% | 1147 |
|
|
2017
Q3 | $12.2M | Buy |
268,553
+53,363
| +25% | +$2.13M | 0.01% | 1276 |
|
|
2017
Q2 | $7.25M | Buy |
215,190
+10,003
| +5% | +$326K | 0.01% | 1570 |
|
|
2017
Q1 | $6.07M | Buy |
205,187
+11,079
| +6% | +$343K | 0.01% | 1641 |
|
|
2016
Q4 | $5.33M | Buy |
194,108
+25,417
| +15% | +$1.02M | 0.01% | 1704 |
|
|
2016
Q3 | $10.4M | Buy |
168,691
+14,875
| +10% | +$450K | 0.01% | 1147 |
|
|
2016
Q2 | $2.93M | Buy |
153,816
+2,766
| +2% | +$51.2K | ﹤0.01% | 1883 |
|
|
2016
Q1 | $2.95M | Buy |
151,050
+3,105
| +2% | +$54.2K | ﹤0.01% | 1841 |
|
|
2015
Q4 | $5.71M | Buy |
147,945
+18,323
| +14% | +$594K | 0.01% | 1427 |
|
|
2015
Q3 | $4.16M | Buy |
129,622
+3,774
| +3% | +$128K | 0.01% | 1593 |
|
|
2015
Q2 | $3.83M | Buy |
125,848
+15,536
| +14% | +$318K | 0.01% | 1724 |
|
|
2015
Q1 | $1.47M | Sell |
110,312
-12,025
| -10% | -$160K | ﹤0.01% | 2224 |
|
|
2014
Q4 | $1.77M | Buy |
122,337
+12,962
| +12% | +$219K | ﹤0.01% | 2084 |
|
|
2014
Q3 | $2.31M | Buy |
109,375
+2,263
| +2% | +$51.1K | ﹤0.01% | 1881 |
|
|
2014
Q2 | $3.19M | Buy |
107,112
+9,560
| +10% | +$302K | 0.01% | 1707 |
|
|
2014
Q1 | $2.35M | Buy |
97,552
+7,824
| +9% | +$199K | ﹤0.01% | 1862 |
|
|
2013
Q4 | $1.83M | Buy |
89,728
+11,042
| +14% | +$328K | ﹤0.01% | 1972 |
|
|
2013
Q3 | $3.74M | Buy |
78,686
+6,089
| +8% | +$235K | 0.01% | 1409 |
|
|
2013
Q2 | $2.8M | Buy |
+72,597
| New | +$2.6M | 0.01% | 1519 |
|
Other funds holding SRPT
EAM
Charles Schwab's SRPT Position: Q2 2026 in Review
Charles Schwab increased its Sarepta Therapeutics (SRPT) stake by 24% in Q2 2026, buying an estimated $3.58M and bringing the position to 980,321 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.
Charles Schwab first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $95.6M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Charles Schwab held 980,321 shares of Sarepta Therapeutics worth $17.6M as of Q2 2026.
- Charles Schwab bought 189,192 Sarepta Therapeutics shares in Q2 2026, an estimated $3.58M.
- Sarepta Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1894 holding.
- Charles Schwab first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Sarepta Therapeutics position peaked at $95.6M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.